The United Kingdom and the United States have established a key commercial pact that will guarantee zero import taxes on British drug products being sold in the US market.
The Terms of the Pact
As part of the deal, the UK has committed to raise expenditure on medicines through the National Health Service (NHS). This pledge guarantees that import taxes on these crucial exports will stay at zero for a timeframe of 36 months.
This deal is in response to recent warnings to dramatically increase tariffs on patented drug imports, with figures mentioned reaching 100%.
"This arrangement between the United Kingdom strengthens the international landscape for new treatments and brings long-overdue fairness to U.S.–U.K. drug exports," a release noted.
Trade Impact
Drugs constitute one of the the United Kingdom's most significant exports to the United States, which is easily the primary destination for major British pharmaceutical firms.
Export figures show that in the 12 months prior to last September, the UK shipped pharmaceutical products worth £11.1bn to the US. This amount accounted for nearly one-fifth of total UK exports in that span.
"This guarantee safeguards work, stimulates capital expenditure and sets the stage for the UK to emerge as a global hub for medical research," a government official commented.
Specific NHS Changes
The agreement involves several key commitments from the UK:
- Price Threshold Increase: The UK will raise the cost ceiling at which it judges new medicines to be prohibitively costly by a quarter.
- Increased NHS Spending: There is a aim to increase total health service expenditure on treatments from 0.3 percent of GDP to 0.6 percent over the coming ten years.
- Rebate Cap: The amount drug companies must return to the NHS to prevent overspending will be capped at 15%. Last year, repayments were more than 20%.
Industry Background
The pact follows a ongoing row between the sector and the UK government over drug pricing and regulatory access.
These tensions were intensified by arguments that American consumers were charged significantly more for the same drugs than consumers in the other developed nations.
Recently, several significant pharmaceutical investments in the UK have been halted or cancelled, while multi-billion-dollar investments have been directed toward projects in the United States.
One official stated that the NHS had to increase expenditure on drugs, noting that its expenditure on drugs had declined as a proportion of its total funding over the previous ten-year period.
